

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### comparision of the effect of Fennelin and diclofenac on primary dysmenorrhea

#### Protocol summary

##### Study aim

Determining and comparing the effect of Fennelin and diclofenac, on primary dysmenorrhea

##### Design

A clinical trial with two intervention groups, Double blind study, Randomized by block method, on 100 patients.

##### Settings and conduct

The study will be conducted on women with dysmenorrhea who refer to specialized gynecology and obstetrics clinics and medical centers. If they have moderate to severe primary dysmenorrhea, they will be included in the study. They will be randomly divided into two intervention groups using the randomized block method. It will be performed in a double-blind manner, so that the patients and the researcher will not know the type of intervention.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: moderate and severe dysmenorrhea. Age between 15-30 years. Regular menstruation

##### Intervention groups

Intervention group 1: Fennelin 30 mg Pearl manufactured by Barij Essential Oil Pharmaceutical Company is taken three times a day for 4 days, one tablet each time and in two menstrual cycles. Intervention group 2: Diclofenac 100 mg tablet manufactured by Hakim Pharmaceutical Company, three times a day for 4 days. And every time one number is consumed in two menstrual periods

##### Main outcome variables

severity of dysmenorrhea, Nausea, vomiting, back pain with dysmenorrhea

#### General information

##### Reason for update

##### Acronym

ندارد

##### IRCT registration information

IRCT registration number: **IRCT20220512054829N2**

Registration date: **2022-10-28, 1401/08/06**

Registration timing: **retrospective**

Last update: **2022-10-28, 1401/08/06**

Update count: **0**

##### Registration date

2022-10-28, 1401/08/06

##### Registrant information

###### Name

Hossein Akbari

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 31 5554 0111

###### Email address

akbari1350\_h@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-07-30, 1401/05/08

##### Expected recruitment end date

2022-08-19, 1401/05/28

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

comparision of the effect of Fennelin and diclofenac on primary dysmenorrhea

##### Public title

effect of Fennelin on primary dysmenorrhoea

##### Purpose

Treatment

### **Inclusion/Exclusion criteria**

#### **Inclusion criteria:**

Regular menstruation Moderate and severe dysmenorrhea Age between 15-30

#### **Exclusion criteria:**

People with underlying diseases User of other drugs genital diseases

### **Age**

From **15 years** old to **30 years** old

### **Gender**

Female

### **Phase**

2

### **Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

### **Sample size**

Target sample size: **100**

### **Randomization (investigator's opinion)**

Randomized

### **Randomization description**

Randomization method: Randomization is done with the block method (Permuted block randomization) so that first All blocks of four that include two codes A and B (6 blocks) are prepared and numbers from 1 to 6 are assigned to each of them. Then, using the table of random numbers, each number from 1 to 6 that is selected, the block corresponding to each code will be written(25 blocks). Based on this, a sequence of codes A and B is prepared for 100 codes (proportionate to the number of samples). Then, each of the letters A and B is randomly assigned to one of the fennelin and diclofenac groups. The same code is recorded on each drug and will remain with the formulation department until the end of the study. At the end of the study, the code of the drugs in the form of A and B will be provided to the statistical analyst for analysis.

### **Blinding (investigator's opinion)**

Double blinded

### **Blinding description**

The drugs in both groups are packaged In vials of one shape and one size in the formulation section of Barij Essential Oil Pharmaceutical Company, then coded based on codes previously prepared using a random number table.

### **Placebo**

Not used

### **Assignment**

Parallel

### **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### 1

#### **Ethics committee**

##### **Name of ethics committee**

Ethics Committee of Faculty of Medicine & Faculty of Dentistry- Kashan University of Medical Science

##### **Street address**

Kashan University of Medical Sciences ,Pezeshk street ,Ghotb ravandi BLVD

##### **City**

Kashan

##### **Province**

Isfahan

##### **Postal code**

8715985131

##### **Approval date**

2022-07-03, 1401/04/12

##### **Ethics committee reference number**

IR.KAUMS.MEDNT.REC.1401.068

## **Health conditions studied**

### 1

#### **Description of health condition studied**

Primary dysmenorrhea

#### **ICD-10 code**

N94.4

#### **ICD-10 code description**

Primary dysmenorrhea

## **Primary outcomes**

### 1

#### **Description**

Moderate to severe dysmenorrhoea according to Andresh and Milsom questionnaire

#### **Timepoint**

Examination of the severity of dysmenorrhea at the beginning of the study before the intervention and on the 1st, 2nd, 3rd and 4th day of menstruation after the intervention.

#### **Method of measurement**

Andres and Milsom questionnaire

## **Secondary outcomes**

### 1

#### **Description**

Nausea with dysmenorrhea

#### **Timepoint**

At the beginning of drug use and days 1, 2, 3, and 4 of dysmenorrhea in two consecutive menstrual periods

#### **Method of measurement**

Andrash and Milsom questionnaire

### 2

#### **Description**

Vomiting with dysmenorrhea

**Timepoint**

At the beginning of drug use and days 1, 2, 3, and 4 of dysmenorrhea in two consecutive menstrual periods

**Method of measurement**

Andrash and Milsom questionnaire

**3****Description**

Back pain with dysmenorrhea

**Timepoint**

At the beginning of drug use and days 1, 2, 3, and 4 of dysmenorrhea in two consecutive menstrual periods

**Method of measurement**

Andrash and Milsom questionnaire

**Intervention groups****1****Description**

Intervention group 1: People take one 30 mg pearl fennelin three times a day after meals with the onset of dysmenorrhea. Each milliliter of this substance contains less than 11.4 mg of anthole as an active ingredient. Phenylin has similar packaging as Diclofenac with the name "Stapin" is designed by Barij Essential Oil Pharmaceutical Company .The drug is used for two menstrual periods and for four days in each period

**Category**

Treatment - Drugs

**2****Description**

Intervention group 2: People take one 100 mg diclofenac tablet three times a day with the onset of dysmenorrhea after meals. Diclofenac has the same packaging as fennelin with the name "Stopain" designed by Hakim Pharmaceutical Company .The drug is used for two menstrual periods and for four days in each period.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Shahid Beheshti Clinic, Kashan

**Full name of responsible person**

Zahra Vahedpour

**Street address**

Shahid Beheshti Hospital, Qutb Rawandi BLVD

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715985191

**Phone**

+98 31 5554 0111

**Fax**

+98 31 5554 0111

**Email**

zink300@gmail.com

**Web page address****Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Dr. Gholamali Hamidi

**Street address**

Kashan University of Medical Sciences, Qutb ravandi BLVD

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715985131

**Phone**

+98 31 5554 0029

**Fax**

+98 31 5554 0029

**Email**

hamidi\_gh@yahoo.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kashan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Hosseini Akbari

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Biostatistics  
**Street address**  
Shahid Beheshti Hospital, Qutb Rawandi Blvd, Kashan  
**City**  
Kashan  
**Province**  
Isfahan  
**Postal code**  
8715985131  
**Phone**  
+98 31 5558 9057  
**Fax**  
+98 31 5558 9057  
**Email**  
akbari1350\_h@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Kashan University of Medical Sciences  
**Full name of responsible person**  
Hossein Akbari  
**Position**  
Associate professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Biostatistics  
**Street address**  
Shahid Beheshti Hospital, Parastar Blvd, Qutb Rawandi Blvd  
**City**  
Kashan  
**Province**  
Isfahan  
**Postal code**  
8715985131  
**Phone**  
+98 31 5558 6057  
**Fax**  
+98 31 5554 0111  
**Email**  
akbari1350\_h@yahoo.cim

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Kashan University of Medical Sciences  
**Full name of responsible person**  
Hossein Akbari  
**Position**  
Associate professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**

Biostatistics  
**Street address**  
Shahid Beheshti Hospital, Parastar Blvd, Qutb Rawandi Blvd  
**City**  
Kashan  
**Province**  
Isfahan  
**Postal code**  
8715985131  
**Phone**  
+98 31 5554 0111  
**Fax**  
+98 31 5554 0111  
**Email**  
akbari1350\_h@yahoo.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

No - There is not a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

### Title and more details about the data/document

It is possible to share some of the data

### When the data will become available and for how long

The access period begins one year after the publication of the article

### To whom data/document is available

All faculty members of medical universities

### Under which criteria data/document could be used

If they want to do more accurate statistical analysis on the data or use newer diagnostic methods to measure the outcome of the intervention

### From where data/document is obtainable

Call and email

### What processes are involved for a request to access data/document

By calling or e-mailing the person in charge and signing a memorandum of cooperation regarding the service he is going to provide and the benefits that will reach the parties.

### Comments